These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 22398088

  • 1. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I, Siffledeen J, Siminoski K, McQueen B, Fedorak RN.
    J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
    [Abstract] [Full Text] [Related]

  • 2. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [Abstract] [Full Text] [Related]

  • 3. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
    Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G.
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):122-32. PubMed ID: 15704046
    [Abstract] [Full Text] [Related]

  • 4. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
    Geller JL, Hu B, Reed S, Mirocha J, Adams JS.
    Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
    Ringe JD, Faber H, Farahmand P, Dorst A.
    Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
    [Abstract] [Full Text] [Related]

  • 6. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
    Park SY, Kang MI, Park HM, Rhee Y, Moon SH, Yoon HK, Koh JM, Chang JS, Kim IJ, Won YY, Park YS, Choi H, Shin CS, Yoon TR, Yun SC, Chung HY, IDEAL Trial Investigators.
    Arch Osteoporos; 2019 Dec 09; 15(1):3. PubMed ID: 31820121
    [Abstract] [Full Text] [Related]

  • 8. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA.
    Calcif Tissue Int; 2000 Oct 09; 67(4):277-85. PubMed ID: 11000340
    [Abstract] [Full Text] [Related]

  • 9. Risedronate improves bone mineral density in Crohn's disease: a complementary mechanism.
    Namazi H.
    J Crohns Colitis; 2012 Jul 09; 6(6):734. PubMed ID: 22483568
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM.
    Epilepsia; 2013 Nov 09; 54(11):1997-2004. PubMed ID: 24010637
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M, Tuzun C, Unlu Z, Tikiz C, Taneli F, Uyanik BS.
    Rheumatol Int; 2006 Jan 09; 26(3):195-200. PubMed ID: 15580349
    [Abstract] [Full Text] [Related]

  • 12. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A, Snelder AA, Mulder H.
    Am J Med; 1995 Sep 09; 99(3):235-42. PubMed ID: 7653482
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.
    Bone; 2010 Apr 09; 46(4):970-6. PubMed ID: 20060082
    [Abstract] [Full Text] [Related]

  • 14. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar 09; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 15. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
    Takakuwa M, Iwamoto J, Itabashi K.
    Clin Drug Investig; 2012 Feb 01; 32(2):121-9. PubMed ID: 22185631
    [Abstract] [Full Text] [Related]

  • 16. The role of risedronate in osteopenia in Crohn's disease.
    Buchan A, Manuel A.
    Gut; 2015 Jan 01; 64(1):185. PubMed ID: 24304669
    [No Abstract] [Full Text] [Related]

  • 17. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM.
    Bone; 2012 Jan 01; 50(1):289-95. PubMed ID: 22061864
    [Abstract] [Full Text] [Related]

  • 18. Authors' response: The role of risedronate in osteopenia in Crohn's disease.
    van Bodegraven AA, Witte BI, Lips P, Crohn and Bone Study Group of the Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2015 Jan 01; 64(1):185-6. PubMed ID: 24569060
    [No Abstract] [Full Text] [Related]

  • 19. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases.
    Ezzat Y, Hamdy K.
    Int J Rheum Dis; 2010 Aug 01; 13(3):259-65. PubMed ID: 20704624
    [Abstract] [Full Text] [Related]

  • 20. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
    Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R.
    Lancet Oncol; 2014 Dec 01; 15(13):1460-1468. PubMed ID: 25456365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.